dm+d

42082003

Articles

How should medicines be dosed in children who are obese?

28 May 2021Review on how to calculate medicine doses in children who are obese which includes a table on commonly prescribed medicines.

Choosing between oral vancomycin options

18 May 2021Local decision makers should choose between the options for giving vancomycin orally. Licensing status and other factors affect decision making.

What injections can be given orally or via enteral feeding tubes?

6 November 2020This updated Medicines Q&A is a quick reference summary to different types of enteral feeding tubes, in relation to medication issues. Not all enteral feeding…

Safety in Lactation: Some other antibacterials

4 November 2020Monitor infant for gastro-intestinal disturbances and oral candida infection, especially if used for prolonged periods or in high doses, although these effects are unlikely to…
Search Articles

Medicine Compliance Aid Stability

VancocinFlynn Pharma Ltd

Flynn Pharma Ltd
Vancocin
Capsules 125mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from moisture
Powder is hygroscopic. Protect from light and store in airtight container. Maximum 7 days in MCA.
1 April 2015

Lactation Safety Information

Yes
Not absorbed from the infant's GI tract
Small amounts in breast milk
24 September 2020

New Medicines

AeroVanc Cystic fibrosis-associated MRSA lung infections - dry powder form in a capsule-based device

Information

AeroVanc
New formulation
Savara
Savara

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Dec 20Savara announce that PIII trial of AeroVanc in cystic fibrosis patients with methicillin-resistant Staphylococcus aureus (MRSA) lung infection failed to meet primary endpoints and development has been discontinued [10].

Category

Dry powder inhalation formulation of vancomycin, a glycopeptide antibiotic.
Prevalence is 1 in 2,500 newborn, with calculated carrier frequency of 1 in 25. Over 9,000 people currently have CF in the UK.
Cystic fibrosis-associated MRSA lung infections - dry powder form in a capsule-based device
Inhalation